550 related articles for article (PubMed ID: 21469925)
1. Evolving strategies: future treatment of glioblastoma.
Chamberlain M
Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
[TBL] [Abstract][Full Text] [Related]
2. Angiogenic inhibition in high-grade gliomas: past, present and future.
Jo J; Schiff D; Purow B
Expert Rev Neurother; 2012 Jun; 12(6):733-47. PubMed ID: 22650175
[TBL] [Abstract][Full Text] [Related]
3. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.
Patel M; Vogelbaum MA; Barnett GH; Jalali R; Ahluwalia MS
Expert Opin Investig Drugs; 2012 Sep; 21(9):1247-66. PubMed ID: 22731981
[TBL] [Abstract][Full Text] [Related]
4. Recurrent high-grade glioma: a diagnostic and therapeutic challenge.
Walbert T; Mikkelsen T
Expert Rev Neurother; 2011 Apr; 11(4):509-18. PubMed ID: 21469924
[TBL] [Abstract][Full Text] [Related]
5. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.
Simpson L; Galanis E
Expert Rev Anticancer Ther; 2006 Nov; 6(11):1593-607. PubMed ID: 17134364
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents.
Minniti G; Muni R; Lanzetta G; Marchetti P; Enrici RM
Anticancer Res; 2009 Dec; 29(12):5171-84. PubMed ID: 20044633
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic therapies in glioblastoma multiforme.
McNamara MG; Mason WP
Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
[TBL] [Abstract][Full Text] [Related]
8. New treatment strategies for malignant gliomas.
Sathornsumetee S; Rich JN
Expert Rev Anticancer Ther; 2006 Jul; 6(7):1087-104. PubMed ID: 16831080
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
Reardon DA; Wen PY
Oncologist; 2006 Feb; 11(2):152-64. PubMed ID: 16476836
[TBL] [Abstract][Full Text] [Related]
10. Current status of antiangiogenic therapies for glioblastomas.
Arrillaga-Romany I; Reardon DA; Wen PY
Expert Opin Investig Drugs; 2014 Feb; 23(2):199-210. PubMed ID: 24320142
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
Chinot OL
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
[TBL] [Abstract][Full Text] [Related]
12. Small molecule inhibitors in children with malignant gliomas.
Herrington B; Kieran MW
Pediatr Blood Cancer; 2009 Sep; 53(3):312-7. PubMed ID: 19434732
[TBL] [Abstract][Full Text] [Related]
13. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic therapy for high-grade gliomas: current concepts and limitations.
De Bonis P; Marziali G; Vigo V; Peraio S; Pompucci A; Anile C; Mangiola A
Expert Rev Neurother; 2013 Nov; 13(11):1263-70. PubMed ID: 24175724
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of evasion to antiangiogenic therapy in glioblastoma.
Rose SD; Aghi MK
Clin Neurosurg; 2010; 57():123-8. PubMed ID: 21280504
[No Abstract] [Full Text] [Related]
16. Primetime for antiangiogenic therapy.
Tabatabai G; Stupp R
Curr Opin Neurol; 2009 Dec; 22(6):639-44. PubMed ID: 19786873
[TBL] [Abstract][Full Text] [Related]
17. [Anti-angiogenic strategies in glioblastoma].
Guillamo JS
Rev Neurol (Paris); 2011 Oct; 167(10):662-7. PubMed ID: 21889779
[TBL] [Abstract][Full Text] [Related]
18. Candidate genes influencing sensitivity and resistance of human glioblastoma to Semustine.
Zhao Z; Liu Y; He H; Chen X; Chen J; Lu YC
Brain Res Bull; 2011 Oct; 86(3-4):189-94. PubMed ID: 21807073
[TBL] [Abstract][Full Text] [Related]
19. Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme.
Chang SM; Butowski NA; Sneed PK; Garner IV
Neurosurg Focus; 2006 Apr; 20(4):E4. PubMed ID: 16709035
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas.
Argyriou AA; Giannopoulou E; Kalofonos HP
Oncology; 2009; 77(1):1-11. PubMed ID: 19439998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
